Tumor development, or tumorigenesis, broadly describes the process by which normal cells gain malignant properties. Tumor development includes growth functions like cellular differentiation, proliferation, and metastasis.
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Mariana Kiehl (Sr. Applications Scientist at Roche Sequencing & Life Science) describes the KAPA Total Prep FFPE workflow, a novel single-tube method for combined sequencing of DNA and R...
Macrophages can mediate phagocytosis of cancer cells and cytotoxic tumor killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system....
Pathology Perspective: Discover the critical need for genomic testing in cancer and explore the differences between traditional tissue biopsies and liquid genomic profiling. We'll dive i...
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations...
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
Description: Join this two-part webinar to learn how capillary electrophoresis (CE) complements sequencing technologies, such as next generation sequencing, that are being used by cancer res...
Description: Join this two-part webinar to learn when capillary electrophoresis is an ideal choice relative to other various sequencing technologies – such as next generation sequencin...
In the era of advanced biotechnology, automation plays a crucial role in accelerating cancer research. Next-generation sequencing (NGS) technology has revolutionized cancer research, but lab...
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
Epigenetic modifications such as DNA methylation have long shown promise as potential biomarkers to diagnose and guide treatment of many human diseases, including multiple types of cancers....
For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identif...
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhib...
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhib...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
Webinar airing too early or too late for you? This webinar will also be available: September 13 at 10:00am PDT, 1:00pm EDT https://www.labroots.com/ms/webinar/dpcr-liquidbiopsy-panel-2 and S...
Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) have each gained attention as promising liquid biopsy markers, offering molecular insights into cancer progression, overall s...
B cell responses within pancreatic ductal adenocarcinoma (PDAC) tumors are associated with improved patient outcomes, yet the specific triggering antigens remain largely unknown. In this web...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Ever wonder what you’re missing in your data? The sheer complexity of today’s flow and mass cytometry datasets demands automated solutions. Machine learning plugins only provide...
The implementation of a preemptive pharmacogenomics (PGx) program in a hospital setting requires a multidisciplinary approach to ensure seamless integration of each stage of the process for...
Mariana Kiehl (Sr. Applications Scientist at Roche Sequencing & Life Science) describes the KAPA Total Prep FFPE workflow, a novel single-tube method for combined sequencing of DNA and R...
Macrophages can mediate phagocytosis of cancer cells and cytotoxic tumor killing, and engage in effective bidirectional interactions with components of the innate and adaptive immune system....
Pathology Perspective: Discover the critical need for genomic testing in cancer and explore the differences between traditional tissue biopsies and liquid genomic profiling. We'll dive i...
Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and color...
Across various stages of the clinical oncology workflow, from panel design to genomic testing and molecular tumor boards, the identification and validation of actionable genomic alterations...
In the last 5 years, the US Food and Drug Administration has approved 4 anti-CD19 chimeric antigen receptor T cell (CART19) products for relapsed/refractory B cell lymphomas and leukemia. Ho...
To bring your cutting-edge cell and gene therapies to the patients that need them as quickly as possible, you need access to the most knowledgeable scientists, innovative technologies, metho...
Description: Join this two-part webinar to learn how capillary electrophoresis (CE) complements sequencing technologies, such as next generation sequencing, that are being used by cancer res...
Description: Join this two-part webinar to learn when capillary electrophoresis is an ideal choice relative to other various sequencing technologies – such as next generation sequencin...
In the era of advanced biotechnology, automation plays a crucial role in accelerating cancer research. Next-generation sequencing (NGS) technology has revolutionized cancer research, but lab...
Patient-derived tumoroids, also known as cancer organoids, hold potential as cost-effective models for cancer immunotherapy research. Patient-derived tumor models, which mimic the tumor micr...
Epigenetic modifications such as DNA methylation have long shown promise as potential biomarkers to diagnose and guide treatment of many human diseases, including multiple types of cancers....
For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identif...
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhib...
Numerous studies have shown that homologous recombination deficiency (HRD) is a genome-wide biomarker present in high grade ovarian and breast cancers. A cancer therapeutic class, PARP inhib...
Webinars will be available for unlimited on-demand viewing after live event. Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the AS...
Liquid biopsy is an emerging area of clinical research, particularly in the context of cancer. As a minimally invasive complementary or alternative approach to tissue biopsies, liquid biopsi...
Webinar airing too early or too late for you? This webinar will also be available: September 13 at 10:00am PDT, 1:00pm EDT https://www.labroots.com/ms/webinar/dpcr-liquidbiopsy-panel-2 and S...
Opens in a new windowOpens an external siteOpens an external site in a new window